In DepthBiomedical Research

NIH center struggles to speed new therapies

See allHide authors and affiliations

Science  27 Sep 2019:
Vol. 365, Issue 6460, pp. 1363
DOI: 10.1126/science.365.6460.1363

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

In September 2012, when National Institutes of Health (NIH) neurologist Chris Austin took charge of a new translational science center, he faced a host of skeptics. In launching the new center, NIH Director Francis Collins said he wanted to re-engineer drug development to speed new treatments to the clinic. But some accused NIH of wanting to become a drug company or solve the pharmaceutical industry's challenges—a notion one former CEO likened to believing in fairies. It fell to Austin to prove that the National Center for Advancing Translational Sciences wasn't going to compete with industry, but could give it new tools. After 7 years, the jury is still out.

View Full Text